NAD+ tablets provide the most accessible delivery format for nicotinamide adenine dinucleotide — the essential coenzyme that declines approximately 50% between young adulthood and age 60 and that serves as the required substrate for cellular energy production (ATP synthesis), DNA repair (PARP enzymes), and the activation of sirtuins (SIRT1-7), the enzyme family most closely associated with longevity biology.

NAD+ tablets provide the most accessible delivery format for nicotinamide adenine dinucleotide — the essential coenzyme that declines approximately 50% between young adulthood and age 60 and that serves as the required substrate for cellular energy production (ATP synthesis), DNA repair (PARP enzymes), and the activation of sirtuins (SIRT1-7), the enzyme family most closely associated with longevity biology. At 500mg per tablet, the PSPeptides NAD+ tablets deliver a substantial dose of the complete, active coenzyme in a convenient oral format that requires no reconstitution, injection, or clinical supervision.

PSPeptides offers NAD+ in three delivery formats — tablets (500mg), injectable vial, and nasal spray — enabling researchers to compare delivery routes and select the format that best matches their specific research design. For a comprehensive overview of NAD+ biology, sirtuin activation, and the age-related decline mechanism, see our complete NAD+ research guide.

Why Do NAD+ Tablets Matter for Longevity Research?

The fundamental challenge of NAD+ supplementation is getting the active coenzyme into cells where it is needed. NAD+ is a relatively large dinucleotide (molecular weight 663.4 Da) that faces bioavailability challenges through every delivery route. The oral tablet format addresses this challenge through the most practical and accessible delivery approach — swallowing a tablet — while accepting the pharmacokinetic tradeoffs that oral delivery entails.

The scientific rationale for NAD+ supplementation rests on one of the most reproducible findings in aging biology: cellular NAD+ levels decline dramatically with age, and this decline mechanistically impairs multiple critical cellular functions simultaneously. Published research has documented that low NAD+ levels slow DNA repair by up to 40% (through impaired PARP function), reduce sirtuin-mediated gene regulation (through substrate depletion), compromise mitochondrial electron transport efficiency (through reduced NADH availability), and promote cellular senescence (through the combined effects of genomic instability, metabolic dysfunction, and impaired stress responses). The Hallmarks of Aging framework published in Cell identified nine core aging mechanisms, and NAD+ decline intersects with at least five of them — making NAD+ one of the most mechanistically broad targets in longevity research.

The 500mg tablet format delivers a clinically meaningful dose of NAD+ in a single unit. Published human intervention studies on NAD+-related compounds have used doses ranging from 250mg to 2,000mg daily, with the majority of studies using 500-1,000mg. The PSPeptides 500mg tablet aligns with the dose range most commonly used in published research, providing sufficient NAD+ to produce measurable increases in circulating NAD+ metabolites based on the clinical evidence base.

How Do NAD+ Tablets Work: Oral Bioavailability Considerations

Understanding the oral bioavailability of NAD+ requires understanding what happens to the molecule during its journey through the gastrointestinal tract, and how this differs from smaller NAD+ precursors like NMN and NR.

When NAD+ is consumed orally as a tablet, it enters the stomach where gastric acid and digestive enzymes begin to break down the dinucleotide structure. A portion of the intact NAD+ may be absorbed through the intestinal epithelium, but a significant fraction is hydrolyzed into its component parts — nicotinamide, adenine, ribose, and phosphate groups. These components are then absorbed individually and can be reassembled into NAD+ inside cells through the salvage pathway (for nicotinamide) and de novo synthesis pathway (for the remaining components).

This means oral NAD+ supplementation works through two parallel mechanisms: direct absorption of intact NAD+ (to whatever extent the molecule survives GI transit and crosses the intestinal epithelium intact), and indirect NAD+ restoration through absorption of hydrolysis products that cells reassemble into NAD+ intracellularly. The relative contribution of each mechanism is an active area of research — published data confirms that oral NAD+ supplementation raises circulating NAD+ metabolite levels, but the precise fraction attributable to direct absorption versus salvage pathway reconstitution is not fully characterized.

This contrasts with NAD+ precursors like NMN (nicotinamide mononucleotide) and NR (nicotinamide riboside), which are smaller molecules (334 Da and 255 Da respectively) designed specifically for oral bioavailability. NMN requires one enzymatic step (NMNAT) to become NAD+, while NR requires two steps (NRK then NMNAT). These precursors have better oral absorption characteristics due to their smaller size but depend on enzymatic conversion to produce the active NAD+ molecule — and the efficiency of these conversion enzymes varies between tissues, between individuals, and with age.

NAD+ Tablets vs NMN vs NR: The Oral Supplementation Comparison

The key tradeoff: NAD+ tablets deliver the complete, active molecule without requiring enzymatic conversion, but the molecule’s larger size reduces oral bioavailability compared to smaller precursors. NMN and NR have better oral absorption but require enzymatic conversion that may be rate-limited by tissue-specific enzyme expression — particularly in aging tissue where enzyme activity declines. For researchers who want to bypass oral bioavailability limitations entirely, PSPeptides’ injectable NAD+ vial provides direct systemic delivery, and the NAD+ nasal spray provides intranasal absorption with potential nose-to-brain delivery.

The Convenience Advantage: Why Tablets Matter for NAD+ Research

The practical significance of the tablet format extends beyond simple convenience — it fundamentally changes the accessibility and scalability of NAD+ research protocols. Injectable NAD+ requires reconstitution with bacteriostatic water, sterile technique, syringe preparation, and subcutaneous injection — a workflow that demands training, supplies, and time for each administration. IV NAD+ infusions require clinical supervision, IV access, and 2-4 hours of infusion time per session. The nasal spray eliminates injection but still requires proper intranasal technique for optimal absorption.

The 500mg tablet eliminates all of these barriers. Open the bottle, take a tablet, swallow with water. For researchers designing long-duration protocols — and NAD+ research increasingly requires multi-month treatment periods to observe meaningful functional outcomes — this simplification compounds over time. A 90-day tablet protocol requires 90 instances of opening a bottle and swallowing a tablet. The same protocol with injectable NAD+ requires 90 reconstitution-preparation-injection cycles. The daily time difference (seconds vs minutes) multiplied by 90 days creates a substantial cumulative difference in researcher time, protocol complexity, and compliance risk.

This convenience also enables larger-scale research. When each participant in a study can self-administer their daily NAD+ by swallowing a tablet, protocols can include more participants without proportionally increasing the supervision and training resources required. For research institutions studying NAD+ across multiple participants simultaneously, the tablet format’s scalability is a practical advantage that influences study design feasibility.

NAD+ Tablets and the Age-Related NAD+ Decline

The biological rationale for NAD+ tablet supplementation centers on reversing or mitigating the age-related NAD+ decline that is one of the most consistently documented molecular changes in biological aging. Published data shows this decline is driven by three converging mechanisms: increased CD38 expression (an ectoenzyme that degrades NAD+ and rises with aging-related inflammation), increased PARP activation (as accumulated DNA damage triggers more frequent repair cycles that consume NAD+), and decreased NAMPT expression (reducing the salvage pathway’s capacity to regenerate NAD+ from nicotinamide).

The consequences of NAD+ depletion cascade across multiple cellular systems simultaneously. Mitochondrial ATP production declines because the electron transport chain requires NAD+/NADH cycling. DNA damage accumulates because PARP enzymes lack sufficient NAD+ substrate to complete repair. Sirtuin-mediated gene regulation fails because SIRT1, SIRT3, and SIRT6 all require NAD+ as a consumable substrate. Cellular senescence accelerates because the combined effects of energy depletion, genomic instability, and metabolic dysfunction push cells toward permanent growth arrest. These interconnected consequences explain why NAD+ decline is associated with virtually every age-related disease — cardiovascular disease, neurodegeneration, metabolic syndrome, sarcopenia, and immune senescence all have NAD+ depletion as a contributing mechanism.

The NAD+ tablet provides the most straightforward approach to addressing this decline: deliver the complete, active coenzyme orally in a dose (500mg) consistent with published human research showing measurable increases in circulating NAD+ metabolites. Whether this biochemical restoration translates to functional aging reversal remains an active research question — the 2026 PRISMA review found consistent biochemical target engagement but heterogeneous functional outcomes — but the biological rationale is among the strongest in the longevity research space.

What Does the Clinical Evidence Show About Oral NAD+ Supplementation?

The 2026 PRISMA-guided systematic review published in Ageing Research Reviews provides the most comprehensive assessment of human NAD+ research. It evaluated 33 human intervention studies (28 randomized, 5 nonrandomized) using NAD+-related compounds administered orally or parenterally.

Biochemical target engagement confirmed: Oral NAD+ supplementation consistently demonstrated increases in circulating NAD+ metabolites — confirming that oral delivery successfully raises the NAD+ pool in human tissue. This finding is important because it validates the oral tablet as a viable delivery route for NAD+ restoration research, despite the bioavailability challenges discussed above.

Functional outcomes are heterogeneous: Effects on functional endpoints — metabolic markers, vascular function, physical performance, cognitive measures — were described as “heterogeneous and often null or endpoint-specific.” Some studies showed improvements in specific metabolic markers, while others found no significant functional changes despite confirmed NAD+ elevation. This suggests that NAD+ supplementation consistently achieves its biochemical target (raising NAD+ levels) but the downstream functional translation depends on factors not yet fully understood — potentially including dose, duration, baseline NAD+ status, age, and tissue-specific enzyme activity.

Safety is well-established: Both oral NAD+ and its precursors were “generally well tolerated over weeks to months” with no serious adverse events attributable to supplementation. The favorable safety profile across dozens of clinical studies supports the use of NAD+ tablets in extended research protocols. For researchers tracking how NAD+ research connects to the broader regulatory landscape, our FDA reclassification guide covers the 2026 changes affecting the peptide and supplement space.

NAD+ Tablets Dosing and Research Protocols

The PSPeptides NAD+ Tablets are supplied at 500mg per tablet — no reconstitution, no preparation, no injection required. Simply swallow with water. This makes the tablet format the most practical option for extended daily research protocols where compliance over weeks or months determines data quality.

Published research protocols vary in dosing, but the most common range is 500-1,000mg daily (one to two tablets). Some studies have used morning dosing to align with the natural circadian peak in metabolic demand, while others have divided doses between morning and evening administration. The optimal timing may depend on the specific research endpoint — metabolic studies may benefit from morning dosing when energy demand peaks, while DNA repair studies may benefit from evening dosing when PARP-mediated repair activity is circadian-regulated. For researchers who are new to NAD+ biology and want to understand the foundational science before designing protocols, our complete NAD+ research guide covers the sirtuin-PARP-CD38 axis, the hallmarks of aging connection, and the full clinical evidence base in detail.

For researchers studying NAD+ through multiple delivery routes simultaneously, PSPeptides’ three-format availability enables comparative pharmacokinetic research: tablets for oral bioavailability, the nasal spray for intranasal absorption, and the injectable vial for direct systemic delivery. Our reconstitution guide covers injectable preparation, and our storage guide provides handling protocols for all formats. Tablets should be stored in a cool, dry place protected from light and moisture. NAD+ is hygroscopic (it absorbs moisture from the air), so keeping tablets in their sealed container until use helps maintain stability and potency throughout the research protocol. Unlike reconstituted injectable solutions that must be used within weeks, properly stored tablets maintain their potency for substantially longer periods — another practical advantage for researchers who purchase in advance for extended protocols.

Combining NAD+ Tablets with Other Longevity Compounds

The NAD+ tablet’s oral convenience makes it easy to incorporate into multi-compound longevity protocols alongside other PSPeptides products.

NAD+ tablets + 5-Amino-1MQ: The most mechanistically synergistic combination. NAD+ tablets increase the supply of the active coenzyme, while 5-Amino-1MQ inhibits NNMT — the enzyme that depletes NAD+ precursors by methylating nicotinamide. Together, they address NAD+ depletion from both the supply side (more NAD+) and the waste side (less precursor degradation). Our 5-Amino-1MQ guide covers the NNMT inhibition mechanism in detail.

NAD+ tablets + Epitalon: NAD+ supports sirtuin-mediated metabolic regulation and DNA repair, while Epitalon activates telomerase for telomere maintenance — addressing different hallmarks of aging through non-overlapping mechanisms. The PSPeptides Epitalon Spray provides convenient intranasal delivery alongside the oral NAD+ tablet.

NAD+ tablets + MOTS-C: NAD+ provides the substrate for sirtuin activation, while MOTS-C activates AMPK — the energy-sensing kinase that forms a mutually reinforcing signaling network with sirtuins. AMPK activation increases NAD+ levels through the salvage pathway, which in turn activates sirtuins, which further enhance metabolic efficiency. The PSPeptides MOTS-C Spray provides intranasal delivery alongside the oral NAD+ tablet for a dual-format protocol.

NAD+ tablets + GHK-Cu: NAD+ addresses the metabolic and genomic dimensions of aging, while GHK-Cu addresses the tissue regeneration dimension through modulation of over 4,000 genes. The GHK-Cu Tablets can be taken alongside NAD+ tablets for an all-oral longevity protocol. For a comprehensive overview of how these longevity compounds interact, see our longevity peptide guide.

Further Reading

For additional peer-reviewed research, see: Hallmarks of Aging framework (López-Otín et al., Cell).

Understanding nad+ tablets is essential for researchers navigating this rapidly evolving field in 2026.

Frequently Asked Questions

What are NAD+ tablets and how do they work?

NAD+ tablets deliver 500mg of nicotinamide adenine dinucleotide — the complete, active coenzyme required for cellular energy production, DNA repair, and sirtuin activation — in an oral format. When consumed, NAD+ is partially absorbed intact and partially hydrolyzed into components that cells reassemble into NAD+ through the salvage pathway. Published research confirms oral NAD+ supplementation raises circulating NAD+ metabolite levels.

Are NAD+ tablets better than NMN or NR supplements?

They work differently. NAD+ tablets deliver the complete coenzyme without requiring enzymatic conversion but have lower oral bioavailability due to larger molecular size. NMN and NR are smaller molecules with better oral absorption but require one or two enzymatic conversion steps to become active NAD+. The choice depends on whether direct delivery (NAD+) or efficient oral absorption (NMN/NR) is more important for the specific research question.

How many NAD+ tablets should I take per day for research?

Published human studies most commonly use 500-1,000mg daily (one to two tablets). Some protocols divide the dose between morning and evening. The 2026 PRISMA systematic review confirmed that this dose range consistently raises circulating NAD+ metabolites and is well-tolerated over weeks to months.

Can NAD+ tablets be combined with other PSPeptides products?

Yes. The most synergistic combination is NAD+ tablets with 5-Amino-1MQ (increases NAD+ supply while preventing precursor waste). NAD+ tablets also complement Epitalon (telomere maintenance), MOTS-C (AMPK mitochondrial signaling), and GHK-Cu (tissue regeneration) — each addressing different hallmarks of aging through non-overlapping mechanisms.

All PSPeptides products are sold exclusively for research and laboratory use.